News & Perspective

Oct 28, 2005

Oct 28, 2005

Chiron wins H5N1 vaccine contract; WHO says virus is changing

(CIDRAP News) – The US government has awarded Chiron Corp. a $62.5 million contract to make a vaccine for H5N1 avian influenza as part of efforts to prepare for a possible human flu pandemic.

Jun 02, 2006

Jun 02, 2006

Epidermal DNA flu vaccine shows promise in phase 1 trial

(CIDRAP News) – An experimental DNA-based flu vaccine that is propelled into the skin on tiny particles instead of injected showed promise in a phase 1 trial involving 36 adults, according to a report published in the May 22 issue of Vaccine.

Jul 18, 2006

Jul 18, 2006

Novartis to build US cell-based flu vaccine plant

(CIDRAP News) – Novartis, the Swiss-based drug manufacturer, today announced plans to build what it says will be the first US plant to make cell-culture-based influenza vaccines.

The facility will be built in Holly Springs, N.C., at a total cost of about $600 million, the company said in a news release. It will be able to produce about 50 million doses of seasonal trivalent (three-strain) flu vaccine annually.

Sep 07, 2006

Sep 07, 2006

Chinese report results for whole-virus H5N1 vaccine

Sept 7, 2006 (CIDRAP News) – In a human trial in China, a whole-virus H5N1 avian influenza vaccine generated an immune response with a relatively low dose of antigen, suggesting that it could be used to immunize more people than may be possible with some other vaccines under development.

Sep 19, 2006

Sep 19, 2006

Sanofi tests H7N1 flu vaccine for pandemic readiness

(CIDRAP News) – Sanofi Pasteur today announced the start of the first clinical trial of an H7N1 influenza vaccine, intended to guard against the threat of a pandemic caused by H7 strains of avian influenza.

Current concern about a flu pandemic focuses mainly on the H5N1 avian flu virus, which has infected at least 247 people and killed 144. But H7 avian flu viruses have caused a number of mild illness cases and one death in the past 3 years.

Oct 24, 2006

Oct 24, 2006

Novartis claims success in trial of cell-based flu vaccine

(CIDRAP News) – Swiss pharmaceutical maker Novartis claimed success last week in a phase 3 clinical trial of a seasonal influenza vaccine produced in cell culture rather than in eggs, the conventional production method.

In a news release, the company said volunteers who received the vaccine had at least as strong an immune response as did volunteers immunized with an egg-based vaccine containing the same flu virus strains.

Apr 12, 2007

Apr 12, 2007

Insect-cell-based flu vaccine looks good in clinical trial

(CIDRAP News) – An influenza vaccine grown in insect cells instead of chicken eggs proved safe and yielded a good immune response in a trial in healthy adults, possibly signaling a significant advance in flu vaccine production technology, according to a report published this week in the Journal of the American Medical Association (JAMA).

Apr 27, 2007

Apr 27, 2007

Panel supports EU approval of cell-based flu vaccine

(CIDRAP News) – A committee that reviews medical product applications for the European Union (EU) yesterday recommended approval of a cell-based seasonal influenza vaccine made by Novartis, improving the company's chance of becoming the first to market a flu vaccine grown in cell culture instead of in eggs.

May 09, 2007

May 09, 2007

EU approves Novartis's 'mock-up' pandemic vaccine

(CIDRAP News) – The European Union (EU) this week approved a "mock-up" influenza vaccine made by Novartis to permit a faster start on vaccine production in the event of a flu pandemic.

Jun 13, 2007

Jun 13, 2007

EU approves Novartis's cell-based flu vaccine

(CIDRAP News) – The European Union (EU) has approved Novartis's seasonal influenza vaccine, Optaflu, putting the Swiss company in a position to become the first to market a flu vaccine grown in cell culture rather than eggs.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»